» Articles » PMID: 12243247

Toll-like Receptor 9, CpG DNA and Innate Immunity

Overview
Journal Curr Mol Med
Specialty Molecular Biology
Date 2002 Sep 24
PMID 12243247
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Innate immunity provides the first line of defense against invading pathogens and is essential for survival in the absence of adaptive immune responses. Innate immune recognition relies on a limited number of germ-line encoded receptors, such as Toll-like receptors (TLRs), that evolved to recognize conserved molecular patterns of microbial origin. To date, ten transmembrane proteins in the TLR family have been described. It is becoming increasingly clear that bacterial CpG DNA and synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG are potent inducers of the innate immune system including dendritic cells (DCs), macrophages, and natural killer (NK) and NKT cells. Recent studies indicate that mucosal or systemic delivery of CpG DNA can act as a potent adjuvant in a vaccine combination or act alone as an anti-microbial agent. Recently, it was shown that TLR9 is essential for the recognition of unmethylated CpG DNA since cells from TLR9-deficient mice are unresponsive to CpG stimulation. Although the effects of CpG DNA on bone marrow-derived cells are beginning to unfold, there has been little or no information regarding the mechanisms of CpG DNA function on non-immune cells or tissues. This review focuses on the recent advances in CpG-DNA/TLR9 signaling effects on the activation of innate immunity.

Citing Articles

The Role of TLRs in Obesity and Its Related Metabolic Disorders.

Campos-Bayardo T, Roman-Rojas D, Garcia-Sanchez A, Cardona-Munoz E, Sanchez-Lozano D, Totsuka-Sutto S Int J Mol Sci. 2025; 26(5).

PMID: 40076851 PMC: 11900219. DOI: 10.3390/ijms26052229.


Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide.

Guerra G, Wendt G, McCoy L, Hansen H, Kachuri L, Molinaro A medRxiv. 2024; .

PMID: 39417102 PMC: 11482862. DOI: 10.1101/2023.10.13.23296963.


Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines.

Zhang W, Zheng X, Coghi P, Chen J, Dong B, Fan X Front Immunol. 2024; 15:1438030.

PMID: 39206192 PMC: 11349682. DOI: 10.3389/fimmu.2024.1438030.


Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies.

Bretto E, Ribaldone D, Caviglia G, Saracco G, Bugianesi E, Frara S Biomedicines. 2023; 11(8).

PMID: 37626745 PMC: 10452708. DOI: 10.3390/biomedicines11082249.


R-DOTAP Cationic Lipid Nanoparticles Outperform Squalene-Based Adjuvant Systems in Elicitation of CD4 T Cells after Recombinant Influenza Hemagglutinin Vaccination.

Henson T, Richards K, Gandhapudi S, Woodward J, Sant A Viruses. 2023; 15(2).

PMID: 36851752 PMC: 9959843. DOI: 10.3390/v15020538.